Tecentriq (atezolizumab) / Roche  >>  Phase 2
Welcome,         Profile    Billing    Logout  

439 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tecentriq (atezolizumab) / Roche
MoST-TAP, NCT06003621: Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients

Recruiting
2
96
RoW
Tiragolumab, RO7092284, MTIG7192A, RG-6058, Anti-TIGIT, Atezolizumab, Tecentriq, MPDL3280A, RG7446, RO5541267
Omico, Hoffmann-La Roche, The George Institute for Global Health, Australia
Solid Tumor, Adult
05/26
11/28
Kirros, NCT06096779: A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis

Recruiting
2
120
US
Atezolizumab, Tecentriq, Bevacizumab, Avastin
Genentech, Inc.
Hepatocellular Carcinoma
05/26
11/26
SAKK 06/19, NCT04630730: Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Recruiting
2
46
Europe
Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC), VPM1002BC, Atezolizumab, Tecentriq™, Cisplatin, Platinol®, Gemcitabine, Gemzar ®
Swiss Group for Clinical Cancer Research
Bladder Cancer
06/26
06/30
BELIEVE, NCT05588388: Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases

Not yet recruiting
2
39
US
Bevacizumab
Kamya Sankar, Genentech, Inc., University of Michigan, VA Ann Arbor Healthcare System
Extensive-stage Small-cell Lung Cancer, Liver Metastases
09/26
09/27
ADVANCE HCC, NCT05137899: Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation Therapy

Recruiting
2
70
Canada
Neoadjuvant
Ontario Clinical Oncology Group (OCOG), Hoffmann-La Roche
Hepatocellular Carcinoma, Portal Vein Tumour Thrombosis
06/26
06/26
FLORA, NCT05690048: Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab

Not yet recruiting
2
48
Europe
Fecal microbiota transfer, FMT, Vancomycin Oral Capsule, Atezolizumab + Bevacizumab, A/B, Placebo Vancomycin Oral Capsule, Placebo Fecal microbiota transfer
Michael Dill, National Center for Tumor Diseases, Heidelberg, German Cancer Research Center, Heidelberg University, University of Cologne, Universitätsmedizin Mannheim
Immunotherapy
07/26
03/27
MOLTO, NCT04082897 / 2018-005028-40: ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Active, not recruiting
2
28
Europe
Obinutuzumab 25 MG/ML [Gazyva], Atezolizumab 60 MG/ML [Tecentriq], Venetoclax Oral Tablet
Niguarda Hospital
CLL Transformation
09/26
12/26
SAABR, NCT04262154: Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Active, not recruiting
2
28
US
Atezolizumab, Abiraterone, Prednisone, GnRH analog, Stereotactic Body Radiotherapy (SBRT), Enzalutamide, Follow up
Memorial Sloan Kettering Cancer Center, Genentech, Inc., Stand Up To Cancer
Metastatic Prostate Cancer
09/26
09/26
NCT05870800: Neoadjuvant Chemoimmunotherapy for Resectable Non-Metastatic Proficient Mismatch Repair (PMMR) Colon Cancer

Not yet recruiting
2
30
US
Tecentriq 1200 MG in 20 ML Injection + Capecitabine 1000 mg/m2 + Oxaliplatin 130 mg/m2, Neoadjuvant Chemoimmunotherapy, Oxaliplatin injection 85mg/m2 + Leucovorin 400mg/m2 + 5-Fluorouracil 2400mg/m2, mFOLFOX6, Oxaliplatin 130mg/m2 + Capecitabine 1000mg/m2, CAPEOX
Baylor College of Medicine, Genentech, Inc.
Stage I Colon Cancer, Stage II Colon Cancer, Stage III Colon Cancer
09/26
01/28
CAPTIV-8, NCT04273061: Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

Recruiting
2
200
Canada
Atezolizumab, TECENTRIQ
British Columbia Cancer Agency, Hoffmann-La Roche
Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Gynecologic Cancer, Sarcoma, Unknown Primary Tumors, Head and Neck Cancer, Skin Cancer
10/26
10/26
NCT05715281: Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

Recruiting
2
15
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Tiragolumab
National Cancer Institute (NCI)
Advanced Rare Malignant Solid Neoplasm, Rare Malignant Solid Neoplasm, Refractory Rare Malignant Solid Neoplasm
10/26
10/26
APOLO, NCT04776447 / 2020-004459-33: Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy.

Recruiting
2
51
Europe
Carboplatin, Carboplatinum, Placlitaxel, Taxol, Atezolizumab, Tecentriq
Fundación GECP
Lung Diseases, Carcinoma, Non-Small-Cell Lung, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Respiratory Tract Neoplasms, Carcinoma Bronchiogenic Stage III, Thoracic Neoplasms
11/26
11/27
ANTONIO, NCT05118724: Atezolizumab in Patients With MSI-h/MMR-D Stage III Colorectal Cancer Ineligible for Oxaliplatin

Recruiting
2
80
Europe
Atezolizumab, Tecentriq
AIO-Studien-gGmbH, Roche Pharma AG, Immodulon Therapeutics Ltd
Colorectal Cancer
11/26
11/26
FINPROVE, NCT05159245: The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

Recruiting
2
250
Europe
Alectinib, Alecensa, Cobimetinib, Cotellic, Vismodegib, Erivedge, Trastuzumab+Pertuzumab, Phesgo, Entrectinib, Rozlytrek, Atezolizumab, Tecentriq, Vemurafenib, Zelboraf, Regorafenib, Stivarga, Apalutamide, Erleada, Abemaciclib, Verzenio, Selpercatinib, Retevmo, Dabrafenib, Tafinlar, Trametinib, Mekinist, Dabrafenib+Trametinib, Tafinlanr+Mekinist, Pralsetinib, Gavreto
Helsinki University Central Hospital
Advanced Cancer, Solid Tumor, Haematological Malignancy
11/26
11/26
NCT05645692 / 2022-002265-15: A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Recruiting
2
240
Europe, US, RoW
Atezolizumab, Tobemstomig, RO7247669, Tiragolumab
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd
Urothelial Cancer
12/26
12/26
NCT05733611: RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Active, not recruiting
2
4
US
RP2, RP3, atezolizumab, bevacizumab
Replimune Inc., Roche Pharma AG
Refractory Metastatic Colorectal Cancer, pMMR, MSS
01/27
03/27
NCT05733598: RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC

Not yet recruiting
2
60
Europe, US
RP3, atezolizumab, bevacizumab
Replimune Inc., Roche Pharma AG
Locally Advanced Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
04/27
07/27
ATEZOBLADDERPRESERVE, NCT04186013: Efficacy of Atezolizumab Concurrent With Radiotherapy in Patients With Muscle-invasive Bladder cáncer

Active, not recruiting
2
39
Europe
Atezolizumab Injection [Tecentriq], External Beam Radiation Therapy (EBRT)
Spanish Oncology Genito-Urinary Group, Roche Farma, S.A, Dynamic Science S.L.
Bladder Cancer
02/27
05/27
NCT05516628: Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma

Recruiting
2
30
RoW
Surgical Resection, Adjuvant Atezolizumab-Bevacizumab Therapy
National Cancer Centre, Singapore, Singapore General Hospital, National University Hospital, Singapore, Changi General Hospital, Sengkang General Hospital, Tan Tock Seng Hospital, Singapore Clinical Research Institute, Genome Institute of Singapore, Institute of Molecular and Cell Biology of Singapore, Cancer Science Institute of Singapore, Duke-NUS Graduate Medical School, Singapore Phenome Centre, Nanyang Technological University, NMRC OF-LCG (OFLCG21Jun-0016)
Hepatocellular Carcinoma
03/27
03/27
NCT06099418: Efficacy and Safety of VB10.16 Alone or in Combination With Atezolizumab in Patients With Advanced Cervical Cancer.

Recruiting
2
130
US
VB10.16, Atezolizumab Injection [Tecentriq], Placebo
Nykode Therapeutics ASA, Roche Pharma AG, GOG Foundation
HPV-Related Cervical Carcinoma, HPV-Related Malignancy, Cervical Cancer
05/27
05/28
DANTE, NCT03421288 / 2017-001979-23: Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness

Recruiting
2
674
Europe
Atezolizumab, TECENTRIQ, 5-Fluorouracil, 5-FU, Calciumfolinat, Leucovorin, Oxaliplatin, ELOXATIN, Docetaxel, TAXOTERE
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Roche Pharma AG
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
05/27
12/27
TIRANUS, NCT05661188: Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma

Recruiting
2
45
Europe
Atezolizumab plus Tiraglolumab
Grupo Espanol Multidisciplinario del Cancer Digestivo, Hoffmann-La Roche
Squamous Cell Carcinoma of the Anal Canal
06/27
06/28
NCT03708224: Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Recruiting
2
55
US
Atezolizumab, Tecentriq, Tocilizumab, Actemra, Tiragolumab, anti-TIGIT
Alain Algazi, Genentech, Inc.
Cancer, Carcinoma, Squamous Cell Carcinoma, Head and Neck Cancer
06/27
06/27
PAPMET2, NCT05411081: Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, Trial

Recruiting
2
200
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography
National Cancer Institute (NCI)
Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
07/27
07/27
DRUP, NCT02925234 / 2015-004398-33: The Drug Rediscovery Protocol ( Trial)

Recruiting
2
1550
Europe
Panitumumab, Vectibix, Olaparib, Lynparza, Dabrafenib, Tafinlar, Nilotinib, Tasigna, Trametinib, Mekinist, Erlotinib, Tarceva, Trastuzumab and Pertuzumab (combination treatment), Herceptin + Perjeta, Vemurafenib and Cobimetinib (combination treatment), Zelboraf + Cotellic, Vismodegib, Erivedge, Regorafenib, Stivarga, Nivolumab, Opdivo, Afatinib, Giotrif, Dabrafenib and trametinib, Tafinlar and Mekinist, Ribociclib, Kisqali, Lenvatinib, Lenvima, Pembrolizumab, Keytruda, Durvalumab, MEDI4736, Rucaparib, Rubraca, Axitinib, Inlyta, Palbociclib, Ibrance, Crizotinib, Xalkori, Sunitinib, Sutent, Cabozantinib, Cabometyx, Abemaciclib, Verzenios, Alectinib, Alecensa, Atezolizumab and Bevacizumab, Tecentriq and Avastin, Ipilimumab and nivolumab, Yervoy and Opdivo, Entrectinib, Rozlytrek, Talazoparib, Talzenna, Dacomitinib, Vizimpro, Lorlatinib, Lorviqua, Erdafitinib, Balversa, Alpelisib, Piqray, Niraparib, Zejula, Pemigatinib, Pemazyre, Selpercatinib, Retsevmo, Tepotinib, Tepmetko
The Netherlands Cancer Institute, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Novartis, Roche Pharma AG, Merck Sharp & Dohme LLC, Boehringer Ingelheim, Ipsen, Eisai Inc., Pfizer, Clovis Oncology - Pharma and, Eli Lilly and Company, Janssen, LP, GlaxoSmithKline, Incyte Corporation, Dutch Cancer Society, Stelvio for Life
Cancer, Tumors, Neoplasm, Neoplasia
09/27
12/27
NCT06043674: A Ph 2 Study of Glofitamab Alone or in Combination With Polatuzumab Vedotin or Atezolizumab in Richter's Transformation

Recruiting
2
66
US
Glofitamab, RO7082859, Obinutuzumab, RO5072759, GA101, GAZYVA, GAZYVARO, Polatuzumab Vedotin, Atezolizumab, Tecentriq, Tocilizumab, Actemra
Christine Ryan, Genentech, Inc.
Chronic Lymphocytic Leukemia, Richter's Transformation
01/28
01/33
NCT05836584: Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Recruiting
2
240
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Capecitabine, Ro 09-1978/000, Xeloda, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Docetaxel, Docecad, RP 56976, RP56976, Taxotere, Taxotere Injection Concentrate, Echocardiography, EC, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Lymphadenectomy, excision of the lymph node, Lymph Node Dissection, Lymph Node Excision, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Surgical Procedure, Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery
National Cancer Institute (NCI)
Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
10/27
10/27
TACOS, NCT05019703: Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, Study

Suspended
2
40
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Cabozantinib
M.D. Anderson Cancer Center
Locally Advanced Osteosarcoma, Metastatic Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma, Unresectable Osteosarcoma
12/27
12/27
LCNEC-ALPINE, NCT05470595: A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung

Recruiting
2
67
Europe
Atezolizumab
Technische Universität Dresden, Roche Pharma AG
Large Cell Neuroendocrine Carcinoma of the Lung
01/28
01/29
SKYSCRAPER-05, NCT04832854: A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Calendar Jan 2025 - Dec 2025: Data from SKYSCRAPER-05 trial for NSCLC
Active, not recruiting
2
50
Europe, US, RoW
Atezolizumab, Tecentriq, Tiragolumab, MTIG7192A, Carboplatin, Cisplatin, Pemetrexed, Gemcitabine, Paclitaxel
Hoffmann-La Roche
Non-Small Cell Lung Cancer (NSCLC)
04/28
04/28
BOUQUET, NCT04931342 / 2020-004936-72: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

Active, not recruiting
2
176
Europe, Canada, US, RoW
Ipatasertib, RO5532961, Cobimetinib, RO5514041, Trastuzumab Emtansine, RO5304020, Atezolizumab, RO5541267, Tecentriq, Bevacizumab, RO4876646, Avastin, Paclitaxel, Giredestrant, Abemaciclib, Inavolisib, Palbociclib, Letrozole, Olaparib, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, Cyclophosphamide
Hoffmann-La Roche, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Ovarian Cancer
05/28
12/28
NCT05935774: OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

Withdrawn
2
30
US
Atezolizumab, MPDL328OA, RG7446, RO5541267, Tecentriq, Biopsy, Bx, Biospecimen Collection, Biological Sample Collection, Computed Tomography, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Electronic Health Record Review, Magnetic Resonance Imaging, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Trabedersen (OT-101), AP 12009
University of Washington, Genentech, Inc., Oncotelic Therapeutics, Inc.
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
07/28
07/28
PERSEVERE, NCT04849364: Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer

Recruiting
2
197
US
Capecitabine, Xeloda, Talazoparib, Talzenna, Pembrolizumab, Keytruda, Inavolisib, GDC-0077
Bryan Schneider, MD, Genentech, Inc., Pfizer, Foundation Medicine, Indiana University, Vera Bradley Foundation for Breast Cancer Research
Breast Cancer, Triple Negative Breast Cancer
01/29
01/34
IMCODE003, NCT05968326: A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected Pancreatic Ductal Adenocarcinoma

Recruiting
2
260
Europe, Canada, US
Autogene cevumeran, Atezolizumab, Tecentriq, mFOLFIRINOX
Genentech, Inc., BioNTech SE
Adenocarcinoma, Pancreatic Ductal
12/29
12/29
NCT00781612 / 2010-021067-32: A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies

Recruiting
2
720
Europe, Canada, Japan, US, RoW
Docetaxel, Paclitaxel, Pertuzumab, Perjeta, Trastuzumab, Herceptin, Trastuzumab Emtansine, Kadcyla; T-DM1, Atezolizumab, Tecentriq
Genentech, Inc., Hoffmann-La Roche
Neoplasm Metastasis
09/29
09/29
NCT05825625: NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

Recruiting
2
35
Europe
Atezolizumab, Tecentriq, Tiragolumab, no other name available
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Thoraxklinik-Heidelberg gGmbH, Roche Pharma AG
Non-small Cell Lung Cancer
11/29
02/30
COGNITION-GUIDE, NCT05332561: Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer

Recruiting
2
240
Europe
Atezolizumab 1200 mg in 20 ML Injection, Tecentriq, Inavolisib, Ipatasertib, Olaparib, Lynparza, Sacituzumab govitecan, Trodelvy, Trastuzumab/pertuzumab, Phesgo
German Cancer Research Center
Early-stage Breast Cancer
03/30
12/30
NCT04989283: Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Withdrawn
2
60
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, External Beam Radiation Therapy, Definitive Radiation Therapy, EBRT, External Beam Radiation, External Beam Radiotherapy, External Beam Radiotherapy (conventional), External Beam RT, external radiation, External Radiation Therapy, external-beam radiation, Radiation, External Beam, Teleradiotherapy, Teletherapy, Teletherapy Radiation, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Pemetrexed, MTA, Multitargeted Antifolate, Pemfexy, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Therapeutic Conventional Surgery
National Cancer Institute (NCI)
Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Superior Sulcus Lung Carcinoma
05/31
05/31
TAPISTRY, NCT04589845 / 2020-001847-16: Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You () Platform Study

Recruiting
2
920
Europe, Canada, Japan, US, RoW
Entrectinib, Rozlytrek, Alectinib, Alecensa, Atezolizumab, Tecentriq, Ipatasertib, Trastuzumab emtansine, Kadcyla, Idasanutlin, Inavolisib, GDC-0077, Belvarafenib, Pralsetinib, Gavreto (US), GDC-6036, Camonsertib
Hoffmann-La Roche
Solid Tumors
09/32
09/32
IMPRESS-Norway, NCT04817956: Improving Public Cancer Care by Implementing Precision Medicine in Norway

Recruiting
2
3000
Europe
Atezolizumab, Atezolizumab combined with bevacizumab, Phesgo (trastuzumab og pertuzumab), Alectinib, vismodegib, entrectinib, Vemurafenib and cobemitinib, Niraparib, Dostarlimab, Ceritinib
Oslo University Hospital, Haukeland University Hospital, St. Olavs Hospital, University Hospital of North Norway, University Hospital, Akershus, Vestre Viken Hospital Trust, Hospital of Southern Norway Trust, Ostfold Hospital Trust, The Hospital of Vestfold, Helse Stavanger HF, Nordlandssykehuset HF, Sykehuset Innlandet HF, Helse Forde, Helse Fonna HF, Helse Nord-Trøndelag HF, Helse Møre og Romsdal HF, Sykehuset Telemark, Lovisenberg Diakonale Hospital
Cancer Metastatic
03/40
04/45
MANTRA-4, NCT06090318: Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Withdrawn
1b/2
NA
Milademetan, RAIN-32, Atezolizumab, TECENTRIQ
Rain Oncology Inc
Advanced Solid Tumor, CDKN2A, NSCLC, Urothelial Carcinoma Bladder, Melanoma, Pancreas Adenocarcinoma, HNSCC, Renal Cell Carcinoma, Mesothelioma, Gastric Cancer
05/23
05/23
NCT05109052: Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating Patients With Unresectable Hepatocellular Carcinoma

Withdrawn
1b/2
48
US
PXS-5505 and Atezolizumab and Bevacizumab
University of Rochester
Hepatocellular Carcinoma, Cancer of Liver
12/28
12/28
2018-003172-12: A Phase 1/2, open-label, multi-center study of the safety and efficacy ofKY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies

Not yet recruiting
1/2
412
Europe
KY1044, Atezolizumab, KY1044, Concentrate for solution for infusion, Tecentriq
Kymab Ltd, Kymab Limited, Kymab Ltd
Advanced/metastatic malignancies, and preferred indications: head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), esophageal cancer, gastric cancer, melanoma, renal cell cancer, pancreatic cancer, cervical cancer, and triple negative breast cancer (BC), selected advanced malignancies, Diseases [C] - Cancer [C04]
 
 
2019-000987-80: A multicentre trial evaluating the combination of a MEK inhibitor and a PDL1 inhibitor in pediatric and adult patients with locally advanced and/or metastatic soft tissue sarcoma Etude multicentrique, menée en ouvert, de Phase I/II visant à évaluer la combinaison d’un inhibiteur de MEK et d’un anti-PDL1 chez des patients pédiatriques et adultes présentant un sarcome des tissus mous de stade avancé ou métastatique

Not yet recruiting
1/2
80
Europe
atezolizumab, cobimetinib, R05541267, R05514041, RO5514041/F12, Concentrate for solution for infusion, Film-coated tablet, Powder for oral solution, TECENTRIQ, COTELLIC
Centre Léon Bérard, INCA
advanced/metastatic soft tissu sarcoma sarcomes des tissus mous de stade avancé/métastatique, soft tissu sarcoma sarcomes des tissus mous, Diseases [C] - Cancer [C04]
 
 
2019-001553-12: Phase I-II Study to Assess the Safety, Tolerability and Efficacy of PM01183 and Atezolizumab in Patients with Advanced Small Cell Lung Cancer that Progressed Following Prior Therapy with Platinum-Based Chemotherapy Estudio de fase I-II para evaluar la seguridad, tolerabilidad y eficacia de PM01183 y atezolizumab en pacientes con cáncer de pulmón de células pequeñas avanzado que hayan progresado tras una quimioterapia previa de platino

Not yet recruiting
1/2
25
Europe
PM01183, Concentrate for solution for infusion, Lyophilisate for solution for infusion, Tecentriq
Fundacion ONCOSUR, Fundación ONCOSUR
Histologically or cytologically confirmed diagnosis of extensive or limited SCLC.Progression to first-line platinum-based chemotherapy.Measurable disease according to RECIST v.1.1. Diagnóstico confirmado histológica o citológicamente de SCLC extenso o limitado.Progresión a la quimioterapia de primera línea a base de platino.Progresión documentada de la enfermedad según RECIST v1.1, diagnosis of small cell lung cancer,progression after treatment with other drugs diagnostico de cáncer de pulmón de células pequeñas,progresión tras tratamiento con otros medicamentos, Diseases [C] - Cancer [C04]
 
 
2018-003120-36: An open-label study in patients with advanced cancer

Not yet recruiting
1/2
174
Europe
IMC-C103C, Atezolizumab, IMC-C103C, 1380723-44, Concentrate for solution for infusion, Tecentriq
Immunocore Limited, Immunocore Limited
Patients with metastatic/unresectable tumors of interest which include NSCLC, esophageal carcinoma, gastric carcinoma, HNSCC, urothelial carcinoma, ovarian carcinoma and synovial sarcoma, Patients with advanced non-small cell lung cancer, head and neck cancer, esophageal cancer, gastric, bladder cancer (also called urothelial cancer), ovarian cancer and synovial sarcoma, Diseases [C] - Cancer [C04]
 
 
2020-002770-27: First-in-human (FIH) study of DRP-104 as single agent and in combination with atezolizumab in patients with advanced solid tumors.

Not yet recruiting
1/2
170
Europe
DRP-104 for Intravenous Infusion, DRP-104 for Subcutaneous Administration, Tecentriq, Powder for concentrate for solution for infusion, Powder for solution for injection, Concentrate for solution for infusion, TECENTRIQ
Dracen Pharmaceuticals, Inc., Dracen Pharmaceuticals, Inc.
Cancer, advanced solid tumors, Cancer, Diseases [C] - Cancer [C04]
 
 
2018-000257-45: A phase Ib/II single-arm study evaluating the safety and efficacy ofcombined immunotherapy with mFOLFOX6, bevacizumab and atezolizumabin advanced-stage biliary cancer Eine einarmige Phase Ib/II Studie zur Untersuchung der Sicherheit und Wirksamkeit einer kombinierten Immuntherapie mit mFOLFOX6, Bevacizumab und Atezolizumab bei fortgeschrittenem Gallengangskarzinom

Not yet recruiting
1/2
35
Europe
Atezolizumab, Bevacizumab, Concentrate for solution for infusion, Tecentriq, Avastin
University Hospital Essen, F. Hoffmann-La Roche Ltd
advanced biliary tract cancer (BTC), advanced biliary tract cancer (BTC), Diseases [C] - Cancer [C04]
 
 
2021-000707-20: A Phase 1/2a study of AFM24 and Atezolizumab in patients with advanced and metastatic cancers Estudio de fase 1/2a de AFM24 y atezolizumab en pacientes con cáncer avanzado y metastásico

Not yet recruiting
1/2
165
Europe
AFM24, Tecentriq, Powder for solution for injection/infusion, Concentrate for solution for infusion, Tecentriq
Affimed GmbH, Affimed GmbH
Advanced/Metastatic EGFR-expressing Cancers Cáncer avanzado/metastásico que expresan EGFR, Advanced/Metastatic Cancers Cáncer avanzado/metastásico, Diseases [C] - Cancer [C04]
 
 
2021-002147-29: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients with Melanoma (Morpheus-Melanoma) Un estudio que evalúa la eficacia y seguridad de múltiples combinaciones de tratamientos en pacientes con melanoma (morfeo-melanoma)

Not yet recruiting
1/2
336
Europe
Atezolizumab, PD1-LAG3, OPDIVO, tiragolumab, ipilimumab, RO5541267, RO7247669, RO7344269, RO7092284, Concentrate for solution for infusion, Tecentriq, OPDIVO®, YERVOY 5 mg/ml concentrate for solution for infusion
Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd
Melanoma Melanoma, Melanoma is a form of skin cancer that begins in the cells (melanocytes) that control the pigment in your skin El melanoma es una forma de cáncer de piel que comienza en las células (melanocitos) que controlan el pigmento de la piel., Diseases [C] - Cancer [C04]
 
 
2SMALL, NCT04253145: Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.

Recruiting
1/2
184
Europe
PM 01183, Lurbinectidin, Atezolizumab, Tecentriq
Fundacion Oncosur
Carcinoma, Small Cell Lung
05/25
05/25
2021-005327-20: TEMPLE - A phase Ib/II study to determine the safety, tolerability andefficacy of Atezolizumab given in combination with thiopurine therapy inpatients with advanced and/or metastatic solid tumors

Not yet recruiting
1/2
39
Europe
Mercaptopurine, Tioguanine, Concentrate and solvent for solution for infusion, Tablet, Tecentriq, Mercaptopurine, Tioguanine
Rigshospitalet, Børnecancerfonden, Roche A/S
Metastatic or advanced solid tumors with an intermediate tumor mutational burden, Incurable solid cancers forms where the tumor is not hypermutated, Diseases [C] - Cancer [C04]
 
 
2020-002927-13: Atezolizumab treatment together with the BEGEV regimen in patients with resistant Hodgkin's lymphoma and candidates for autologous stem cell transplantation. Trattamento di atezolizumab associato a combinazione BEGEV in pazienti con linfoma di Hodgkin resistente e candidati al trapianto autologo di cellule staminali.

Not yet recruiting
1/2
140
Europe
Atezolizumab, Bendamustina, Gemcitabina, Vinorelbina, [IMP2], [IMP3], [IMP4], [IMP5], [IMP6], [IMP1], Concentrate for solution for infusion, Powder for concentrate for solution for infusion, TECENTRIQ - 840 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 20 ML (60 MG/ML) - 1 FLACONCINO, BENDAMUSTINA ACCORD - 2,5 MG/ML POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - 5 FLACONCINI DA 40 ML, BENDAMUSTINA ACCORD - 2,5 MG/ML POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - 5 FLACONCINI DA 10 ML, Gemcitabina cloridrato, VINORELBINA ACTAVIS - 10 MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO DI VETRO DA 5 ML, TECENTRIQ - 1200 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 20 ML (60 MG/ML) - 1 FLACONCINO
FONDAZIONE ITALIANA LINFOMI ONLUS, Roche S.p.A.
Refractory/relapsed Hodgkin Lymphoma. Linfoma di Hodgkin ricaduto/refrattario., Refractory/relapsed Hodgkin Lymphoma. Linfoma di Hodgkin ricaduto/refrattario., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2021-004155-16: Phase Ib study investigating dose, safety and efficacy of [177Lu]Lu-DOTA-TATE in patients with Extensive Stage Small Cell Lung Cancer (specific form of lung tumour)

Not yet recruiting
1/2
200
Europe
Tislelizumab, Solution for infusion, Kit for radiopharmaceutical preparation, Concentrate for solution for infusion, Lutathera, NETSPOT, Baize’an
Novartis Pharma AG, Novartis Pharma AG
Extensive-Stage Small Cell Lung Cancer, Specific form of lung tumour, Diseases [C] - Cancer [C04]
 
 
VENEZO-LUNG, NCT04487756: Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer

Active, not recruiting
1/2
20
Europe
Atezolizumab 1200 mg in 20 ML Injection, Tecentriq, ADC Vaccine, Autologous Dendritic cell (ADC) vaccine, Dendritic cell (DC) vaccine, Carboplatin, Carboplatino (Teva/Accord/Pharmacia)
Instituto Oncológico Dr Rosell, Roche Pharma AG, Fundacion Clinic per a la Recerca Biomédica
Extensive-stage Small Cell Lung Cancer
08/24
10/24
NCT03881878: TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After Surgery

Not yet recruiting
1/2
67
RoW
TAHP and AHP, TAHP plus AC and AHP
Samsung Medical Center
HER2-positive Breast Cancer
10/22
10/22
2021-003229-31: Integration of immunotherapy into first-line chemotherapy voor patients with epithelioid malignant pleural mesothelioma Toevoeging van immuuntherapie aan de eerstelijnschemotherapie voor patiënten met epitheliale longvlieskanker

Not yet recruiting
1/2
15
Europe
cryopreserved Wilms' tumor 1 (WT1) mRNA-electroporated dendritic cells, WT1/DC, Suspension for injection, Concentrate for solution for infusion, Tecentriq
Antwerp University Hospital, Kom op tegen Kanker, NV Roche SA
Malignant pleural mesothelioma, epithelioid subtype (stage I-IV) Maligne pleuraal mesothelioma, epithelioïde subtype (stadium I-IV), Asbestos cancer Asbestkanker (longvlieskanker), Diseases [C] - Cancer [C04]
 
 
2021-003189-11: A clinical study to test the safety and efficacy of GB1211 in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC). studio in aperto seguito da una fase randomizzata in doppio cieco a gruppi paralleli con studio di estansione, per indagare la sicurezza e l'efficacia di GB1211 in cominazione con Atezolizumab in pazienti affetti da carcinoma polmonare non a piccole cellule

Not yet recruiting
1/2
77
Europe
GB1211, Tecentriq, [GB1211], [RO5541267], Capsule, soft, Concentrate for emulsion for infusion, TECENTRIQ 1200 mg
Galecto Biotech AB, Galecto Biotech AB
Study to investigate the safety and efficacy of GB1211 (a galectin-3 inhibitor) in combination with atezolizumab in patients with Non-Small Cell Lung Cancer (NSCLC). pazienti affetti da carcinoma polmonale non a piccole cellule (NSCLC), Non-Small Cell Lung Cancer (NSCLC) pazienti affetti da tumore al polmone non a piccole cellule, Diseases [C] - Cancer [C04]
 
 
2019-004505-27: A Phase 1b/2 study of derazantinib as monotherapy and combination therapy with paclitaxel, ramucirumab or atezolizumab in patients with HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations (FIDES-03)

Not yet recruiting
1/2
314
Europe
Derazantinib, Paclitaxel EVER Pharma 6 mg/ml, Cyramza 100 mg/10ml, Tecentriq 1,200 mg, Cyramza 500 mg/50ml, [Ramucirumab], [Atezolizumab], [Paclitaxel], [Derazantinib], Capsule, hard, , Concentrate for solution for infusion, Paclitaxel EVER Pharma 6 mg/ml, Cyramza 100 mg/10ml, Tecentriq 1,200 mg, Cyramza 500 mg/50ml
Basilea Pharmaceutica International Ltd., Basilea Pharmaceutica International Ltd., Allschwil, Basilea Pharmaceutica International Ltd, Allschwil, Basilea Pharmaceutica International AG, Basilea Pharmaceutica International Ltd.
HER2-negative gastric adenocarcinoma harboring FGFR genetic aberrations, Stomach cancer, Diseases [C] - Cancer [C04]
 
 
NCT03853707: Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer

Completed
1/2
28
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Capecitabine, Ro 09-1978/000, Xeloda, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Ipatasertib, GDC-0068, RG-7440, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
01/23
09/23
NOA-20, NCT03158389 / 2015-002752-27: NCT Neuro Master Match - N²M²

Completed
1/2
228
Europe
APG101, Alectinib, Alecensa, Idasanutlin, Atezolizumab, Vismodegib, Erivedge, Temsirolimus, Troisel, Palbociclib, Ibrance
University Hospital Heidelberg, German Cancer Aid, German Cancer Research Center, National Center for Tumor Diseases, Heidelberg
Glioblastoma, Adult
02/23
02/23
NCT02523469: ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer

Completed
1/2
58
US
ALT-803, Nivolumab, OPDIVO
Medical University of South Carolina, Altor BioScience
Non-small Cell Lung Cancer
02/23
02/23
2019-003300-12: Clinical evaluation of virus therapy for malignant melanoma

Not yet recruiting
1/2
50
Europe
LOAd703, Tecentriq, LOAd703, Suspension for injection, Concentrate for solution for infusion, Tecentriq
Lokon Pharma AB, Lokon Pharma AB
Malignant melanoma, Malignant melanoma, Diseases [C] - Cancer [C04]
 
 
NCT04123470: A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma

Completed
1/2
26
Europe, US
delolimogene mupadenorepvec, LOAd703, atezolizumab
Lokon Pharma AB, Precision Oncology LLC
Malignant Melanoma
07/23
07/23
GALLANT-1, NCT05240131: A Study to Investigate the Safety and Efficacy of GB1211 (a Galectin-3 Inhibitor) in Combination With Atezolizumab in Patients With Non-Small Cell Lung Cancer (NSCLC).

Active, not recruiting
1/2
88
Europe
GB1211, Placebo, Atezolizumab
Galecto Biotech AB, Linical Europe GmbH, Hoffmann-La Roche
Non-Small Cell Lung Cancer
05/24
11/25
NCT05253053: To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Recruiting
1/2
114
RoW
TT-00420, Combination Product: Atezolizumab, Combination Product: Nab-Paclitaxel
TransThera Sciences (Nanjing), Inc.
Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer
09/24
12/24
IMC-C103C-101, NCT03973333: Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Terminated
1/2
75
Europe, US
IMC-C103C, Atezolizumab, TECENTRIQ
Immunocore Ltd
Select Advanced Solid Tumors
09/23
09/23
2021-001060-23: A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination with Tiragolumab with or Without Atezolizumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Not yet recruiting
1/2
118
Europe
Mosunetuzumab, Tocilizumab, Atezolizumab, Tiragolumab, RO7030816, RO4877533, RO5541267, RO7092284, Solution for injection, Concentrate for solution for infusion, RoActemra®, Tecentriq®
F. Hoffman-La Roche Ltd, F.Hoffman-La Roche Ltd
Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL), Non-Hodgkin Lymphoma is a cancer of the lymphatic system. It develops when the body makes abnormal B lymphocytes., Diseases [C] - Cancer [C04]
 
 
IceCAP, NCT03673787: A Trial of Ipatasertib in Combination With Atezolizumab

Recruiting
1/2
87
Europe
ipatasertib, Atezolizumab
Institute of Cancer Research, United Kingdom, Hoffmann-La Roche
Solid Tumor, Glioblastoma Multiforme, Prostate Cancer Metastatic
11/23
11/23
GO29781, NCT02500407: A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Checkmark Data from GO29781 trial for 3L+ follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from GO29781 trial for 3L+ follicular lymphoma at ASH 2022
Checkmark Data from GO29781 trial for follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from GO29781 trial for follicular lymphoma at ASH 2022
Checkmark Subgroup Analysis from pivotal P2 GO29781 study at EHA 2022
More
Active, not recruiting
1/2
836
Europe, Canada, US, RoW
BTCT4465A (Mosunetuzumab) IV, Atezolizumab, Tecentriq, BTCT4465A (Mosunetuzumab) SC
Genentech, Inc.
Lymphocytic Leukemia, Chronic, Lymphoma, Non Hodgkin
11/25
11/25
NCI-2016-01233, NCT02935361: Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

Active, not recruiting
1/2
33
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Guadecitabine, DNMT inhibitor SGI-110, S110, SGI-110
University of Southern California, National Cancer Institute (NCI), Van Andel Research Institute
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
11/24
11/25
NCT02989584: A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

Active, not recruiting
1/2
54
US
Atezolizumab, Gemcitabine, Cisplatin
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Bladder Cancer, Metastatic Bladder Cancer, Urothelial Carcinoma
12/24
12/24
NCT04029181: ImmunoPET With an Anti-CD8 Imaging Agent

Active, not recruiting
1/2
47
Europe
Anti-CD8 PET imaging agent
University Medical Center Groningen
Metastatic Cancer, Unresectable Malignant Neoplasm
12/22
12/24
PDL1-BEY-LUNG, NCT05325684: PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung Cancer

Not yet recruiting
1/2
30
NA
PD-L1 inhibitor
The Affiliated Hospital of Qingdao University
Efficacy, Safety
12/23
12/23
NCT05315713: An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Completed
1/2
8
Europe, Canada, US, RoW
Mosunetuzumab SC, Tiragolumab, Atezolizumab, Tocilizumab
Hoffmann-La Roche
Non-Hodgkin Lymphoma, Follicular Lymphoma
07/23
07/23
NCT03502785 / 2018-000309-21: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

Active, not recruiting
1/2
35
US
INO-5401, INO-9012, Atezolizumab, CELLECTRA™ 2000
Inovio Pharmaceuticals
Urothelial Carcinoma
12/24
12/24
R-IMMUNE, NCT03127007 / 2016-004526-41: Safety and Efficacy of Atezolizumab Combined to Preoperative Radio-chemotherapy in Localized Rectal Cancer

Active, not recruiting
1/2
54
Europe
Atezolizumab, Tecentriq, MPDL3280a, 5-FU based radio-chemotherapy
Grand Hôpital de Charleroi, Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Rectal Neoplasms
02/24
09/24
NCT04471727: Study in Patients With Advanced Cancers Associated With Expression of DLL3

Recruiting
1/2
162
US
HPN328, Atezolizumab
Harpoon Therapeutics
Small-Cell Lung Cancer, Neuroendocrine Carcinoma
07/25
12/25
NCT04793399: Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients

Terminated
1/2
9
Europe
Bosutinib 400 MG Monotherapy, Bosulif, Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection, Bosulif + Tecentriq
Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica, Pfizer, Roche Farma, S.A
Chronic Phase-Chronic Myeloid Leukemia
09/21
09/21
IMMCO-1, NCT05000294: Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Recruiting
1/2
29
US
Atezolizumab, Tecentriq, Tivozanib, Fotivda
University of Florida, Genentech, Inc., Aveo Oncology Pharmaceuticals
Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Vulvar Cancer, Prostate Cancer
12/24
12/25
TRIO-US L-06 , NCT03830918: Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

Recruiting
1/2
74
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Niraparib, MK-4827, MK4827, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ
Jonsson Comprehensive Cancer Center, Translational Research in Oncology-U.S, Tesaro, Inc.
Advanced Malignant Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
01/25
01/26
NCT03901573: High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Terminated
1/2
31
US
NT-I7, efineptakin alfa, rhIL-7-hyFc, atezolizumab, Tecentriq
NeoImmuneTech, Immune Oncology Network
Melanoma, Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma
08/23
08/23
IMC-F106C-101, NCT04262466 / 2019-004046-16: Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors

Recruiting
1/2
727
Europe, Canada, US, RoW
IMC-F106C, IMC-F106C and pembrolizumab, IMC-F106C and chemotherapy, IMC-F106C and monoclonal antibodies and chemotherapy, IMC-F106C and tebentafusp, IMC-F106C and bevacizumab, IMC-F106C and kinase inhibitors
Immunocore Ltd
Select Advanced Solid Tumors
06/26
06/26
NCT03568656 / 2018-000285-10: Study to Evaluate CCS1477 in Advanced Tumours

Recruiting
1/2
350
Europe, US
CCS1477, Abiraterone acetate, Enzalutamide, Darolutamide, Olaparib, Atezolizumab
CellCentric Ltd.
Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
03/24
03/24
NCT03206047: Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Active, not recruiting
1/2
75
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, CDX-1401, Guadecitabine, DNMT inhibitor SGI-110, S110, SGI-110, Laboratory Biomarker Analysis, Poly ICLC, Hiltonol, Poly I:Poly C with Poly-L-Lysine Stabilizer, poly-ICLC, PolyI:PolyC with Poly-L-Lysine Stabilizer, Polyinosinic-Polycytidylic Acid Stabilized with Polylysine and Carboxymethylcellulose, Polyriboinosinic-Polyribocytidylic Acid-Polylysine Carboxymethylcellulose, Stabilized Polyriboinosinic/Polyribocytidylic Acid
National Cancer Institute (NCI)
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
03/25
03/25
NCT03829501: Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer

Active, not recruiting
1/2
280
Europe, US, RoW
KY1044, KY1044 and atezolizumab
Kymab Limited, Sanofi
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer, Gastric Cancer, Melanoma, Renal Cell Carcinoma, Pancreatic Cancer, Cervical Cancer, Triple Negative Breast Cancer, Advanced Cancer, Metastatic Cancer
08/24
08/24
WAKING, NCT04166721: WaKING: Wnt and checKpoint INhibition in Gastric Cancer

Recruiting
1/2
52
Europe
Atezolizumab, DKN-01
Royal Marsden NHS Foundation Trust
Metastatic Esophageal Cancer, Metastatic Gastric Cancer
05/24
09/25
MEKiAUTO, NCT04214418: Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies

Active, not recruiting
1/2
175
US
Cobimetinib, Hydroxychloroquine, Atezolizumab, TECENTRIQ, MPDL3280A
Columbia University, Genentech, Inc.
Gastrointestinal Cancer
06/24
09/24
COMBATBIL, NCT05052099: Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer

Recruiting
1/2
35
Europe
mFOLFOX6, Atezolizumab and Bevacizumab
University Hospital, Essen
Biliary Tract Cancer
06/24
06/24
IDeate-Lung03, NCT06362252: A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer

Not yet recruiting
1/2
149
NA
Ifinatamab deruxtecan, I-DXd, Atezolizumab, Carboplatin, Etoposide
Daiichi Sankyo, Merck Sharp & Dohme LLC
Extensive Stage-small Cell Lung Cancer
11/26
12/26
NCT05756907: Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer

Recruiting
1/2
165
US, RoW
SON-1010
Sonnet BioTherapeutics, Hoffmann-La Roche
Advanced Solid Tumor, Platinum-resistant Ovarian Cancer
06/24
05/25
NCT04101357 / 2019-003593-17: Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

Active, not recruiting
1/2
55
Europe, US
BNT411, Atezolizumab, Carboplatin, Etoposide
BioNTech SE
Solid Tumor, Extensive-stage Small Cell Lung Cancer
01/24
07/24
NCT05394337: Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

Recruiting
1/2
10
US
Atezolizumab, MPDL3280A, TECENTRIQ, Tiragolumab
M.D. Anderson Cancer Center
Metastatic Malignancy
07/24
07/24
GOING, NCT04170556: Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma

Active, not recruiting
1/2
69
Europe
Regorafenib, Nivolumab
Fundacion Clinic per a la Recerca Biomédica, Apices Soluciones S.L.
Hepatocellular Carcinoma
08/24
08/24
NCT04467723: Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC

Recruiting
1/2
25
US
Atezolizumab, Pirfenidone
University of Kansas Medical Center, parkview cancer institute
NSCLC Stage IV, NSCLC, Recurrent
08/24
08/25
NCI-2024-01398, NCT06287775: Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Not yet recruiting
1/2
45
NA
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736, Echocardiography, EC, Iadademstat, ORY 1001, ORY-1001, RG 6016, RG6016, RO 7051790, RO7051790, trans-N1-((1R,2S)-2-Phenylcyclopropyl)-1,4-cyclohexanediamine, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning
National Cancer Institute (NCI)
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
01/26
01/26
MORPHEUS-EC, NCT03281369 / 2016-004529-17: A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Active, not recruiting
1/2
410
Europe, US, RoW
5-Fluorouracil (5-FU), Leucovorin, Folinic acid, Oxaliplatin, Atezolizumab, Tecentriq, Cobimetinib, Cotellic, Ramucirumab, Paclitaxel, PEGylated recombinant human hyaluronidase (PEGPH20), BL-8040, Linagliptin, Cisplatin, Tiragolumab, RO7092284
Hoffmann-La Roche, Halozyme Therapeutics, BioLineRx, Ltd.
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma
08/24
04/25
TEMPLE, NCT05276284: Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy

Recruiting
1/2
39
Europe
Atezolizumab, 6-mercaptopurine, 6-thioguanine
Kristoffer Rohrberg
Solid Tumor, Adult, Metastatic Cancer
08/24
08/25
NCT04440735: A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors

Recruiting
1/2
125
US
DSP107, Atezolizumab
Kahr Medical
Advanced Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer
09/24
12/24
NCT05109442: Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Recruiting
1/2
148
Europe, US, RoW
AFM24, Atezolizumab 840 MG in 14 ML Injection
Affimed GmbH
Advanced Solid Tumor
09/24
06/25
 

Download Options